Dr. Watabe notes that in his home of Osaka, Japan, there is a new cyclotron (MP-30X, Sumitomo) dedicated to the production of ...

The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Wolfgang Fendler discussing the pro stance for the future of FAP. Fibroblast Activation ...

Whereas it may appear that Ac-PSMA has had a slower development trajectory compared to Lu-PSMA radioligand therapy, Dr. Eiber ...

The study met its primary endpoint of radiographic progression free survival, which was significantly prolonged with the ...

The 2026 PSMA & Beyond conference featured a challenges of radioligand therapy session and a presentation by Dr. Daniel Childs discussing long term marrow toxicity rates and risk factors. 177 ...

Dr. Morris then discussed the PCWG4 Rule of 5 for defining radiographic progression free survival in the post-flare period. If there are <=5 new metastases, a confirmatory scan is performed, and if ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Stephanie Lira discussing scaling operations in theranostics clinical research. There has been tremendous ...

The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Philipp Backhaus discussing the initial experience with APC3. The history of ACP3 goes back ...

The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Lena Unterrainer discussing the con stance for the future of FAP. The primary challenge with ...

The 2026 PSMA & Beyond conference featured a session on challenges of radioligand therapy and a presentation by Dr. Inès Camille Azrour discussing renal toxicity associated with PSMA targeted therapy.

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Tanya Dorff discussing antibody drug conjugates and BiTEs and their role in prostate cancer. Dr.

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Rahul Aggarwal discussing DLL3 and whether target expression determines the method of targeting.